Publication | Closed Access

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

OncologyMedicineReceptor Tyrosine KinaseSolid TumoursPharmacotherapyAnti-cancer AgentCancer TreatmentPharmacologyRadiation Oncology